Controlled nonviral gene delivery and expression using stable neural stem cell line transfected with a hypoxia‐inducible gene expression system
- 14 December 2010
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 12 (12) , 990-1001
Abstract
Background: Nonviral ex vivo local gene therapy systems consisting of regulated gene expression vectors and cellular delivery platforms represent a novel strategy for tissue repair and regeneration. We introduced a hypoxia‐regulated plasmid‐based system into mouse neural stem cells (NSCs) as an efficient gene expression and delivery platform for rapid, robust and persistent hypoxic/ischemic‐regulated gene expression in the spinal cord.Methods: A synthetic hypoxia‐responsive erythropoietin (Epo) enhancer, the SV40 minimal promoter and the luciferase (Luc) reporter gene were incorporated in a DsRed‐expressing double‐promoter plasmid for cell lipofection and Zeocin‐selection to establish a hypoxia‐regulated stable NSC line (NSC‐Epo‐SV‐Luc). A nonhypoxia‐regulated stable NSC line (NSC‐SV‐Luc) was also established as a control.Results: Under the transcriptional regulation of the Epo enhancer, in vitro luciferase expression in NSC‐Epo‐SV‐Luc, but not in NSC‐SV‐Luc, was sensitively augmented according to the strength and duration of the hypoxic stimulus and was quickly down‐regulated to a low basal level after reoxygenation of the hypoxic cells. Furthermore, deoxygenation of the reoxygenated cells clearly enhanced the luciferase activity again. After transplantation into a rat spinal cord injury (SCI) model, only NSC‐Epo‐SV‐Luc showed ischemic injury‐specific luciferase expression Notably, the engineered NSC lines kept the neural differentiation potential and retained the hypoxia‐regulated luciferase expression after differentiation.Conclusions: We propose that NSCs engineered with the Epo‐SV‐therapeutic gene will be valuable for developing a controllable stem cell‐mediated nonviral gene therapy for SCI or other central nervous system diseases accompanied with chronic or episodic hypoxic/ischemic stresses. Copyright © 2010 John Wiley & Sons, Ltd.Keywords
This publication has 45 references indexed in Scilit:
- Ex Vivo VEGF Delivery by Neural Stem Cells Enhances Proliferation of Glial Progenitors, Angiogenesis, and Tissue Sparing after Spinal Cord InjuryPLOS ONE, 2009
- Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapyProceedings of the National Academy of Sciences, 2009
- Double Oxygen–sensing Vector System for Robust Hypoxia/Ischemia-regulated Gene Induction in Cardiac Muscle In Vitro and In VivoMolecular Therapy, 2008
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- Neurodegeneration and cell replacementPhilosophical Transactions of the Royal Society B: Biological Sciences, 2007
- Human Neural Stem Cells Over-Expressing VEGF Provide Neuroprotection, Angiogenesis and Functional Recovery in Mouse Stroke ModelPLOS ONE, 2007
- Effective cell and gene therapy in a murine model of Gaucher diseaseProceedings of the National Academy of Sciences, 2006
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006
- Synergistic enhancement of bone formation and healing by stem cell–expressed VEGF and bone morphogenetic protein-4Journal of Clinical Investigation, 2002
- Mammalian Neural Stem CellsScience, 2000